-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Ultragenyx Pharmaceutical Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2017 to Q3 2024.
- Ultragenyx Pharmaceutical Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $303K, a 53.4% decline year-over-year.
- Ultragenyx Pharmaceutical Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was -$2.09M, a 590% decline year-over-year.
- Ultragenyx Pharmaceutical Inc. annual Income Tax Expense (Benefit) for 2023 was -$1.83M, a 132% decline from 2022.
- Ultragenyx Pharmaceutical Inc. annual Income Tax Expense (Benefit) for 2022 was $5.7M, a 446% increase from 2021.
- Ultragenyx Pharmaceutical Inc. annual Income Tax Expense (Benefit) for 2021 was $1.04M, a 13.5% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)